Toll Free : + 1-888-961-4454 | Int'l : + 91 (788) 802-9103 | support@researchdive.com
LI2009382 |
Pages: NA |
Jun 2020 |
Osteopontin antibody refers to a phosphorylated acidic glycoprotein that mediates various biological functions. Osteopontin plays an important role in multiple physiological processes. OPN is further used in the pathogenesis of various disease states such as glomerulonephritis, cancer, chronic inflammatory diseases, and atherosclerosis. Osteopontin interacts with multiple integrins and mediates cell adhesion, survival, and migration in different cell types. Osteopontin is also known to function as Th1 cytokine, playing the key role in autoimmune diseases, and promoting cell-mediated immune responses. Osteopontin, other than its inflammation functions, also acts as a potent inhibitor of vascular clarification and regulator of biomineralization.
Osteopontin has a vital role in the human bone systems and ensures they remain strong and healthy. They have wide usage for multiple other health concerns as well such as chronic inflammatory diseases and in general improving the immune system. Growing cases of bone weakening, bone injuries due to multiple reasons, and various other immune weakening diseases are driving the market growth. Further, growing cancer patients and the geriatric population have created a major demand rise for Osteopontin antibodies. Osteopontin plays a significant role in the healing process of cancer patients and strengthening the weak body and immune system as well as helps with the protection and prevention of multiple other diseases in the geriatric population. According to a report by the World Health Organization from September 2018, cancer is the second leading cause of deaths globally, with approximate 9.6 million deaths in the year 2018. With the growing age, diseases and other health problems also increase majorly in the geriatric population for which the osteopontin antibodies are used majorly. These numbers have majorly been growing since the past years globally, causing a widespread adoption of osteopontin antibodies treatments. Owing to all these factors the demand for osteopontin antibodies is increasing majorly which will drive the market growth during the forecast period.
The osteopontin market is facing major issues in its growth due to low awareness and even lower adoption rates for various purposes. The market is only restricted to some developed countries with a robust technological infrastructure to carry out the research and development work. Major parts or regions globally lack the availability of osteopontin antibodies as a product due to the underdeveloped or poor healthcare sectors. Various regions do not possess enough technology and infrastructural facilities to develop, produce, test, and sell these products also due to the high-cost involvement to carry out all such activities.
Technological upgradations and advancements will enable already developed regions to promote and forward the technology further to the underdeveloped and poor regions. These regions are deprived of knowledge, technology, and funds to conduct any activities related to osteopontin, but technological upgradations will make the development process of osteopontin much easy and cost-effective. Further, increased investments by various regions and particularly governments to upgrade the prevailing healthcare conditions and infrastructure will allow the osteopontin market to increase its reach. This will create lucrative market opportunities for growth as various products like food items and other medicinal drugs will start incorporating osteopontin antibodies as raw materials and will eventually increase its customer base. Also, major research and development activities due to the rising focus on benefits from osteopontin antibodies will create more opportunities by making it available across the globe at comparatively low prices. All these factors will help to increase the awareness and adoption of osteopontin antibodies in the global market and will create massive growth opportunities.
The mouse segment will have a dominating share in the global market and is expected to register a significant revenue during the forecast period. Mouse and humans are both mammals and share a huge percentage of DNA. Owing to highly resembling body factors and greater availability they are potentially the most suitable mode of testing and examination to carry out various research work. Increased investments in the research and development sector, wide availability, easy approval by governments for use in research institutes and labs are driving the market growth.
The human segment is anticipated to grow at a fast pace in the osteopontin antibody market during the forecast period. The technological upgradations, developing healthcare infrastructure, and growing investments in the research and development sector to study potential osteopontin applications are driving the market growth. In vitro transfection experiments have shown that downregulating osteopontin gene expression reduced or slowed the progression of breast cancer. Further, research work across the globe has suggested that enhanced osteopontin expression leaves a high metastatic phenotype of cancer cells. Also,, osteopontin acts as a key cytokine regulating tissue repair, serves as a chemotactic molecule in order to provide inflammatory cells at the site of injury, and regulates the immune system at different levels. Owing to all these benefits osteopontin antibodies usage and application have significantly grown and helped in the market growth.
The medical segment is expected to register maximum growth in the osteopontin antibody market during the forecast timeframe. Growing R&D activities and studies have shown positive indications of osteopontin antibodies and they can be utilized in multiple applications. Osteopontin antibodies could be used to develop potential drugs and vaccines for multiple health issues like glomerulonephritis, cancer, chronic inflammatory diseases, and atherosclerosis. Owing to these benefits and growing investments in the healthcare sector the demand for osteopontin antibodies will majorly increase for medical purposes.
North America region is anticipated to hold the largest share in the osteopontin antibody market during the forecast period. Robust healthcare infrastructure, major investments in research and development sector, availability of the majority of educational institutes and other laboratories, and wide awareness and adoption are the major factors driving the market growth. Further, growing cancer patients and the geriatric population particularly in the U.S and Canada is propelling the market growth in the region.
Source: Research Dive Analysis
Some of the significant global osteopontin antibody market players include ProMab, R&D Systems, Inc., Arla Foods Ingredients Group P/S, LifeSpan BioSciences, Inc, Novus Biologicals, Sigma-Aldrich Co., Santa Cruz Biotechnology, Inc., OriGene Technologies, Inc., Proteintech Group, Inc., and NKMAX Co., Ltd.
Market players prefer inorganic growth strategies to expand into local markets.
Global osteopontin antibody market players are dondentrating on advanced product development and merger & acquisition. These are the strategies followed by established organizations. To emphasize more on the competitor analysis of market players, Porter’s five forces model is explained in the report.
Aspect |
Particulars |
Historical Market Estimations |
2018-2019 |
Base Year for Market Estimation |
2019 |
Forecast timeline for Market Projection |
2020-2027 |
Geographical Scope |
North America, Europe, Asia-Pacific, LAMEA |
Segmentation by Type |
|
Segmentation by Application |
|
Key Countries Covered |
U.S., Canada, Germany, France, Spain, Russia, Japan, China, India, South Korea, Australia, Brazil, and Saudi Arabia |
Key Companies Profiled |
|
* Taxes/Fees, If applicable will be added during checkout. All prices in USD.
Have a question ?
Enquire To BuyNeed to add more ?
Request Customization